Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.

Details

Ressource 1Download: 30863405_BIB_6975012892E2.pdf (3105.68 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_6975012892E2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.
Journal
Frontiers in immunology
Author(s)
Botelho N.K., Tschumi B.O., Hubbell J.A., Swartz M.A., Donda A., Romero P.
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Publication state
Published
Issued date
2019
Peer-reviewed
Oui
Volume
10
Pages
294
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Cross-presenting Xcr1 <sup>+</sup> CD8α DCs are attractive APCs to target for therapeutic cancer vaccines, as they are able to take up and process antigen from dying tumor cells for their MHCI-restricted presentation to CD8 T cells. To this aim, we developed fusion proteins made of the Xcr1 ligand Xcl1 fused to an OVA synthetic long peptide (SLP) and IgG1 Fc fragment. We demonstrated the specific binding and uptake of the Xcl1 fusion proteins by Xcr1 <sup>+</sup> DCs. Most importantly, their potent adjuvant effect on the H-2Kb/OVA specific T cell response was associated with a sustained tumor control even against the poorly immunogenic B16-OVA melanoma tumor. The increased tumor protection correlated with higher tumor infiltration of antigen-specific CD8+ T cells, increased IFNγ production and degranulation potential. Altogether, these results demonstrate that therapeutic cancer vaccines may be greatly improved by the combination of SLP antigen and Xcl1 fusion proteins.
Keywords
Xcl1, Xcr1+ DC, antigen cross-presentation, synthetic long peptides, therapeutic cancer vaccine
Pubmed
Web of science
Open Access
Yes
Create date
11/03/2019 18:09
Last modification date
20/09/2020 6:27
Usage data